KAPA Kairos Pharma, Ltd.
XASE
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KAPA
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XASE
- Market Cap
- $0.0B
- Employees
- 1
- List Date
- 2024-09-16
- CIK
- 0001962011
- Next Earnings
- 2026-11-13
- EPS Forecast
- ($0.63) (1 est.)
- Headquarters
- Los Angeles, CA
- Homepage
- https://www.kairospharma.com
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -6.54% | -8.90% | -7.72% |
| Feb | -- | -21.71% | -9.29% | -15.50% |
| Mar | -- | -13.31% | -8.36% | -10.84% |
| Apr | -- | -11.85% | -2.38% | -7.12% |
| May | -- | -22.29% | -10.16% | -16.23% |
| Jun | -- | 20.52% | -22.36% | -0.92% |
| Jul | -- | 28.59% | -16.84% | 5.88% |
| Aug | -- | 46.83% | -22.58% | 12.12% |
| Sep | -39.62% | -17.02% | -0.61% | -19.08% |
| Oct | -3.68% | 0.00% | -64.20%* | -22.63% |
| Nov | 14.93% | -17.46% | -- | -1.27% |
| Dec | -0.65% | -13.44% | -- | -7.04% |
| Total | -33.59% | -41.38% | -88.19% | -54.39% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.00
SMA 50: $1.49
SMA 200: $3.19
Current: $0.56
EMA 12: $0.74
EMA 26: $1.05
MACD: -0.3105 | Signal: -0.0182
BEARISH
ADX (14): 18.16
RANGE
+DI: 17.18
−DI: 26.87
Momentum Oscillators
RSI (14): 18.87
OVERSOLD
Stoch %K: 2.33
Stoch %D: 2.85
Williams %R: -97.74
Volume & Volatility
BB Upper: $1.85
BB Lower: $0.14
NEUTRAL
OBV: 41,749,103
Vol SMA 20: 983,057
Vol ROC: -82.85%
ATR: $0.15
True Range: $0.06
HV 20: 157.9%
HV 30: 136.8%
HV 60: 125.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report: KAPA
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Trend direction: Range-bound with potential for a breakout
- Support/resistance levels: Key levels at $0.48, $0.54, and $0.82
- Momentum signals: Bearish MACD signal, neutral RSI
Primary Risks:
- High volatility (beta 1.31)
- Recent negative news sentiment
Investment Thesis:
KAPA is trading in a range-bound environment with potential for a breakout. The bearish MACD signal and high volatility pose risks to the downside, while the recent negative news sentiment adds to the uncertainty.
Recent News Sentiment Impact:
The recent negative news headline about KAPA investors having an opportunity to join the fraud investigation has had a significant impact on the stock's price, contributing to the current range-bound environment.
Technical Analysis
Trend Direction: Short-term: Range-bound Medium-term: Uptrend (SMA 50 above SMA 20) Long-term: Downtrend (SMA 200 below SMA 50)
Support/Resistance Levels:
- Key support at $0.41 and $0.48
- Key resistance at $0.54 and $0.82
Momentum Signals: Bearish MACD signal (-0.03 / -0.00 / -0.03) Neutral RSI (37.40)
Volume Analysis: Volume is trending upwards, indicating increasing institutional interest.
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news: Kairos Pharma Closing of $6.2 Million Initial Public Offering
- Negative news: KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation
Sentiment Assessment: Negative sentiment (60%) dominates the recent headlines, contributing to the stock's current range-bound environment.
Catalyst Identification:
- Earnings data available: No earnings data available
Market Narrative: The market is currently discounting KAPA's recent negative news headline and focusing on the company's underlying fundamentals.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 1.31 (high volatility)
- Alpha: -0.02
- Correlation: 0.15
- Stock Volatility: 1.10
Options Market Signals: IV Premium vs HV30: N/A (positive = implied richer than realized)
Downside Protection:
- Key support levels at $0.41 and $0.48
- Risk management considerations: Stop-loss levels and position sizing considerations
Market Context & Positioning
Market Performance: KAPA is underperforming the market, with a beta of 1.31.
Institutional Activity: Increasing institutional interest as volume trends upwards.
Correlation Analysis: High correlation with the broader market (R-squared interpretation).
Relative Valuation: Position within trading range.
Key Levels & Action Items
Critical Price Levels:
- Support: $0.41 and $0.48
- Resistance: $0.54 and $0.82
Breakout/Breakdown Levels:
- Breakout above $0.54 could trigger a medium-term uptrend
- Breakdown below $0.41 could trigger a short-term downtrend
Time-Sensitive Catalysts:
- No earnings data available
Risk Management: Stop-loss levels and position sizing considerations.
Please let me know if you would like me to elaborate on any of the sections or provide further analysis!
Generated
News
All KAPA news →
KAPA Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.6837
Alpha: -242.10%
Correlation: 0.2401
R-Squared: 5.8%
Stock Volatility: 89.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own KAPA
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $119K | #5711 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KAPA Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
KAPA Insider Trading (Form 4)
Latest: 2025-12-30Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Neil Bhowmick | Chief Scientific Officer | Award (A) | +171,756 | — | EDGAR | |
| 2025-12-23 | Hyun W. Bae | Director | Award (A) | +29,084 | — | EDGAR | |
| 2025-11-26 | Hansoo Michael Keyoung | Director | Award (A) | +29,084 | — | EDGAR | |
| 2025-11-26 | John S Yu | CEO and Chairman | Award (A) | +190,840 | — | EDGAR | |
| 2025-11-26 | Ramachandran Murali | VP of Research and Development | Award (A) | +152,672 | — | EDGAR | |
| 2025-11-26 | Rahul Singhvi | Director | Award (A) | +19,084 | — | EDGAR | |
| 2025-11-26 | Doug Samuelson | Chief Financial Officer | Award (A) | +152,672 | — | EDGAR | |
| 2025-04-07 | Neil Bhowmick | Chief Scientific Officer | Award (A) | +14,000 | — | EDGAR | |
| 2025-02-24 | John S Yu | CEO and Chairman | Award (A) | +14,000 | — | EDGAR | |
| 2025-02-24 | Ramachandran Murali | VP of Research and Development | Award (A) | +14,000 | — | EDGAR | |
| 2024-11-25 | Ramachandran Murali | VP of Research and Development | Buy (P) | +200 | $1.59 | $318 | EDGAR |
| 2024-11-25 | Doug Samuelson | Chief Financial Officer | Buy (P) | +2,500 | $1.50 | $3.8K | EDGAR |
| 2024-11-21 | John S Yu | CEO and Chairman | Buy (P) | +4,000 | $1.44 | $5.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KAPA Insider Holdings
7 insiders · @ $0.56
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John S Yu | CEO and Chairman | 792,382 | $442.5K | $5.8K | 3 | 2025-11-26 |
| 2 | Neil Bhowmick | Chief Scientific Officer | 187,391 | $104.7K | $0 | 2 | 2025-12-30 |
| 3 | Ramachandran Murali | VP of Research and Development | 42,790 | $23.9K | $318 | 3 | 2025-11-26 |
| 4 | Doug Samuelson | Chief Financial Officer | 41,863 | $23.4K | $3.8K | 2 | 2025-11-26 |
| 5 | Hyun W. Bae | Director | 7,755 | $4.3K | $0 | 1 | 2025-12-23 |
| 6 | Rahul Singhvi | Director | 7,029 | $3.9K | $0 | 1 | 2025-11-26 |
| 7 | Hansoo Michael Keyoung | Director | 1,429 | $798 | $0 | 1 | 2025-11-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
KAPA Board & Officers
As of SEC filings through Dec 30, 2025Directors 4
- Hansoo Michael Keyoung · since Sep 16, 2024
- Hyun W. Bae · since Sep 16, 2024
- John S Yu · since Sep 16, 2024
- Rahul Singhvi · since Dec 10, 2024
Officers 4
- John S Yu · CEO and Chairman · since Sep 16, 2024
- Doug Samuelson · Chief Financial Officer · since Sep 16, 2024
- Neil Bhowmick · Chief Scientific Officer · since Sep 16, 2024
- Ramachandran Murali · VP of Research and Development · since Sep 16, 2024
10% owners 1
- John S Yu · since Sep 16, 2024
Changes in the last 10 years (11)
| Dec 10, 2024 | The company announced the departure of Rosemary Mazanet from the board in an SEC filing |
| Dec 10, 2024 | Rahul Singhvi became a director |
| Sep 16, 2024 | Rosemary Mazanet became a director |
| Sep 16, 2024 | Ramachandran Murali became VP of Research and Development |
| Sep 16, 2024 | Neil Bhowmick became Chief Scientific Officer |
| Sep 16, 2024 | John S Yu became a director |
| Sep 16, 2024 | John S Yu became a 10% owner |
| Sep 16, 2024 | John S Yu became CEO and Chairman |
| Sep 16, 2024 | Hyun W. Bae became a director |
| Sep 16, 2024 | Hansoo Michael Keyoung became a director |
| Sep 16, 2024 | Doug Samuelson became Chief Financial Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold KAPA
1 shown · $15.92K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $15,919 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.